{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:31:34Z","timestamp":1793424694718,"version":"4.5.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) remains a leading cause of end-stage renal disease worldwide. Despite advances in renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors, sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRAs), substantial residual renal risk persists. Endothelin-1 (ET-1), primarily via endothelin A (ETA) receptor activation, plays a central role in glomerular injury, inflammation, and fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>This narrative review summarizes current evidence on the mechanistic basis and clinical translation of ETA receptor antagonists (ERAs) in DKD. Relevant preclinical and clinical studies were identified through structured literature searches of PubMed, Embase, and Web of Science, focusing on mechanistic insights, therapeutic efficacy, and safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Preclinical studies across diabetic models (e.g., streptozotocin-induced and db\/db mice) demonstrate that ETA antagonism reduces glomerular hypertension, preserves podocyte integrity, and attenuates inflammatory and fibrotic signaling pathways. In clinical settings, the SONAR trial showed that atrasentan significantly reduced the risk of renal events (hazard ratio ~0.65) and achieved approximately 30\u201340% reduction in urinary albumin-to-creatinine ratio (UACR) in selected responders. However, ERA therapy is associated with fluid retention and increased heart failure risk. Notably, a biomarker-guided enrichment strategy, based on early albuminuria response during a run-in phase, improved patient selection and benefit\u2013risk balance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ETA receptor antagonists represent a promising mechanism-based adjunctive therapy for DKD. Their future role is likely to be integrated within combination regimens alongside SGLT2 inhibitors and MRAs, guided by biomarker-driven precision medicine approaches to optimize efficacy while minimizing adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1808445","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:27:48Z","timestamp":1778819268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review"],"prefix":"10.3389","volume":"17","author":[{"given":"Muqin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Lianyungang","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The Affiliated Lianyungang Hospital of XuZhou Medical University","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, Lianyungang Clinical College of Nanjing Medical University.","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The First Affiliated Hospital of Kangda College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Kangda College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Lianyungang","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The Affiliated Lianyungang Hospital of XuZhou Medical University","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, Lianyungang Clinical College of Nanjing Medical University.","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The First Affiliated Hospital of Kangda College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, The First People\u2019s Hospital of Lianyungang","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Lianyungang","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The Affiliated Lianyungang Hospital of XuZhou Medical University","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, Lianyungang Clinical College of Nanjing Medical University.","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The First Affiliated Hospital of Kangda College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Lianyungang","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The Affiliated Lianyungang Hospital of XuZhou Medical University","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, Lianyungang Clinical College of Nanjing Medical University.","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The First Affiliated Hospital of Kangda College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First People\u2019s Hospital of Lianyungang","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The Affiliated Lianyungang Hospital of XuZhou Medical University","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, Lianyungang Clinical College of Nanjing Medical University.","place":["Lianyungang, China"]},{"name":"Department of Endocrinology, The First Affiliated Hospital of Kangda College of Nanjing Medical University","place":["Lianyungang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9111134","article-title":"Effects of allicin on pathophysiological mechanisms during the progression of nephropathy associated to diabetes","volume":"9","author":"Arellano-Buend\u00eda","year":"2020","journal-title":"Antioxid (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27249035","article-title":"The role of oxidative stress-mediated inflammation in the development of T2DM-induced diabetic nephropathy: Possible preventive action of tannins and other oligomeric polyphenols","volume":"27","author":"Sahakyan","year":"2022","journal-title":"Molecules"},{"key":"B3","first-page":"93","article-title":"Normalization of the ratio of nitric oxide and peroxynitrite by promoting eNOS dimer activity is a new direction for diabetic nephropathy treatment","volume":"74","author":"Kan","year":"2022","journal-title":"Sheng Li Xue Bao"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad052","article-title":"The complex pathology of diabetic nephropathy in humans","volume":"38","author":"Kriz","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12182\/20231160102","article-title":"Non-classical clinical types and pathological changes of diabetic kidney disease: A review","volume":"54","author":"Fang","year":"2023","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7504798","article-title":"Research progress on the pathological mechanisms of podocytes in diabetic nephropathy","volume":"2020","author":"Zhang","year":"2020","journal-title":"J Diabetes Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169035","article-title":"Podocyte death in diabetic kidney disease: Potential molecular mechanisms and therapeutic targets","volume":"25","author":"Zhong","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2023.104877","article-title":"Urinary exosomes from patients with diabetic kidney disease induced podocyte apoptosis via microRNA-145-5p\/Srgap2 and the RhoA\/ROCK pathway","volume":"134","author":"Han","year":"2023","journal-title":"Exp Mol Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13036-022-00299-4","article-title":"Pathophysiology of mesangial expansion in diabetic nephropathy: Mesangial structure, glomerular biomechanics, and biochemical signaling and regulation","volume":"16","author":"Thomas","year":"2022","journal-title":"J Biol Eng"},{"key":"B10","article-title":"Association of systemic immune-inflammation index and systemic inflammation response index with diabetic kidney disease in patients with type 2 diabetes mellitus","volume":"17","author":"Liu","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108378","article-title":"Study on the relationship between lipoprotein (a) and diabetic kidney disease","volume":"37","author":"Wang","year":"2023","journal-title":"J Diabetes Complic"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.622692","article-title":"Rotten to the cortex: Ceramide-mediated lipotoxicity in diabetic kidney disease","volume":"11","author":"Nicholson","year":"2020","journal-title":"Front Endocrinol (Laus)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107954","article-title":"Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors","volume":"32","author":"Kogot-Levin","year":"2020","journal-title":"Cell Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666230328151108","article-title":"Biomarkers for diabetic nephropathy with a focus on kidney injury molecule-1 (KIM-1)","volume":"20","author":"Khonsha","year":"2024","journal-title":"Curr Diabetes Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0004563220983851","article-title":"Plasma miR-193a-3p can be a potential biomarker for the diagnosis of diabetic nephropathy","volume":"58","author":"Hong","year":"2021","journal-title":"Ann Clin Biochem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.22.123","article-title":"Pathological validation of the Japanese Renal Pathology Society classification and challenges in predicting renal prognosis in patients with diabetic nephropathy","volume":"41","author":"Kim","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.80.3.7883838","article-title":"Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo","volume":"80","author":"Ferri","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12895","article-title":"Hyperinsulinemia augments endothelin-1 protein expression and impairs vasodilation of human skeletal muscle arterioles","volume":"4","author":"Mahmoud","year":"2016","journal-title":"Physiol Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13086","article-title":"Endothelin-1 in the pathophysiology of obesity and insulin resistance","volume":"21","author":"Jenkins","year":"2020","journal-title":"Obes Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2022.09.005","article-title":"Gender differences in genotypic distribution of endothelin-1 gene and endothelin receptor A gene in pulmonary hypertension associated with rheumatic mitral valve disease","volume":"74","author":"Mehra","year":"2022","journal-title":"Indian Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15383","DOI":"10.1038\/s41598-020-72352-5","article-title":"Distribution and relative expression of vasoactive receptors on arteries","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40620-024-02072-w","article-title":"Targeting endothelin signaling in podocyte injury and diabetic nephropathy-diabetic kidney disease","volume":"38","author":"Empitu","year":"2025","journal-title":"J Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00498.2019","article-title":"Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy","volume":"318","author":"Hudkins","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s40200-024-01514-3","article-title":"Short-term effect of atorvastatin on renal oxidative stress, inflammation, and fibrosis in a rat model of streptozotocin-induced diabetes","volume":"24","author":"Mayyas","year":"2025","journal-title":"J Diabetes Metab Disord"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae214","article-title":"Selective endothelin A receptor antagonism in chronic kidney disease: Improving clinical application","volume":"40","author":"Moedt","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2020.1781901","article-title":"Effect of Acacia Senegal on TGF-\u03b21 and vascular mediators in a rat model of diabetic nephropathy","volume":"128","author":"Mohammed","year":"2022","journal-title":"Arch Physiol Biochem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.04.024","article-title":"Targeting tissue-resident memory CD8(+) T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis","volume":"30","author":"Li","year":"2022","journal-title":"Mol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071644","article-title":"Metformin is associated with the inhibition of renal artery AT1R\/ET-1\/iNOS axis in a rat model of diabetic nephropathy with suppression of inflammation and oxidative stress and kidney injury","volume":"10","author":"Dawood","year":"2022","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2174\/1389450124666221026152647","article-title":"The mechanistic role of different mediators in the pathophysiology of nephropathy: A review","volume":"24","author":"Singh","year":"2023","journal-title":"Curr Drug Targets"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1332388","article-title":"Kinetics of endothelin-1 and effect selective ET(A) antagonism on ET(B) activation: A mathematical modeling analysis","volume":"15","author":"Hallow","year":"2024","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000045906","article-title":"Effects of endothelin receptor antagonists on the progression of diabetic nephropathy","volume":"87","author":"Hocher","year":"2001","journal-title":"Nephron"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112823","article-title":"Enhanced cardiorenal protective effects of combining SGLT2 inhibition, endothelin receptor antagonism and RAS blockade in type 2 diabetic mice","volume":"23","author":"Vergara","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200312000-00009","article-title":"Nephroprotective effect of bosentan in diabetic rats","volume":"42","author":"Cosenzi","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2012.03.032","article-title":"Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist","volume":"91","author":"Sen","year":"2012","journal-title":"Life Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200306000-00009","article-title":"Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats","volume":"41","author":"Witte","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42748","article-title":"Current status of endothelin receptor antagonists in pulmonary arterial hypertension: A combined study results and pharmacology-based review","volume":"15","author":"Nahar","year":"2023","journal-title":"Cureus"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000001950","article-title":"Aprocitentan: The first endothelin receptor antagonist for resistant hypertension","volume":"32","author":"Nguyen","year":"2025","journal-title":"Am J Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241273218","article-title":"Pressing update: Aprocitentan for the treatment of hypertension","volume":"59","author":"Phillips","year":"2025","journal-title":"Ann Pharmacother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5c00421","article-title":"Unveiling the carbonic anhydrase inhibitory profile of aprocitentan: Kinetic and structural characterization","volume":"16","author":"Angeli","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"B42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s13256-022-03571-9","article-title":"Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: A case report","volume":"16","author":"Lattanzio","year":"2022","journal-title":"J Med Case Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/mnh.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1869720","article-title":"Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease","volume":"30","author":"Provenzano","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641874","article-title":"Treatment with endothelin-A receptor antagonist BQ123 attenuates acute inflammation in mice through T-cell-dependent polymorphonuclear myeloid-derived suppressor cell activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2021.02.002","article-title":"Reduced glomerular endothelial thrombomodulin is associated with glomerular macrophage infiltration in diabetic nephropathy","volume":"191","author":"van Aanhold","year":"2021","journal-title":"Am J Pathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206056","article-title":"Endothelin inhibitors in chronic kidney disease: New treatment prospects","volume":"13","author":"Rakotoarison","year":"2024","journal-title":"J Clin Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043427","article-title":"Endothelin receptor antagonists in kidney disease","volume":"24","author":"Mart\u00ednez-D\u00edaz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895501","article-title":"Endothelin B receptor immunodynamics in pulmonary arterial hypertension","volume":"13","author":"Tabeling","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae021","article-title":"Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy","volume":"39","author":"Nagasawa","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cca.2020.03.008","article-title":"The endothelin system as target for therapeutic interventions in cardiovascular and renal disease","volume":"506","author":"Eroglu","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1406","article-title":"Endothelin limits insulin action in obese\/insulin-resistant humans","volume":"56","author":"Lteif","year":"2007","journal-title":"Diabetes"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.100.8.820","article-title":"Insulin stimulates both endothelin and nitric oxide activity in the human forearm","volume":"100","author":"Cardillo","year":"1999","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.12.3517","article-title":"Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes","volume":"51","author":"Mather","year":"2002","journal-title":"Diabetes"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12064","article-title":"Endothelin antagonists for diabetic and non-diabetic chronic kidney disease","volume":"76","author":"Kohan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2500294","article-title":"Endothelin receptor antagonists for diabetic kidney disease: back to the future","volume":"34","author":"Anyfanti","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06326-x","article-title":"Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial","volume":"68","author":"Smeijer","year":"2025","journal-title":"Diabetologia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19325","article-title":"Endothelin receptor antagonists as a potential treatment of diabetic nephropathy: A systematic review","volume":"13","author":"Ahmad","year":"2021","journal-title":"Cureus"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030824","article-title":"Endothelin receptor antagonists: status quo and future perspectives for targeted therapy","volume":"9","author":"Enevoldsen","year":"2020","journal-title":"J Clin Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12933-023-01964-8","article-title":"Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease","volume":"22","author":"Smeijer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v11.i11.553","article-title":"Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review","volume":"11","author":"Zhang","year":"2020","journal-title":"World J Diabetes"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14411","article-title":"Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Zhou","year":"2021","journal-title":"Diabetes Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2721","article-title":"Organic anion transporter gene variants associated with plasma exposure and long-term response to atrasentan in patients with diabetic kidney disease","volume":"112","author":"Smeijer","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2025.2487212","article-title":"Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis","volume":"47","author":"Cheungpasitporn","year":"2025","journal-title":"Ren Fail"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2024.2424824","article-title":"Aprocitentan: a new emerging prospect in the pharmacotherapy of hypertension","volume":"33","author":"Naseralallah","year":"2024","journal-title":"Blood Press"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad183","article-title":"Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial","volume":"39","author":"Heerspink","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1756234","article-title":"Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients","volume":"36","author":"Tahara","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2552901","article-title":"Aprocitentan: a new horizon in the treatment of hypertension","volume":"26","author":"Fields","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-024-01709-x","article-title":"Unveiling the future: precision pharmacovigilance in the era of personalized medicine","volume":"46","author":"Silva","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34572","article-title":"Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: A review","volume":"15","author":"Alkhatib","year":"2023","journal-title":"Cureus"},{"key":"B73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12882-021-02587-5","article-title":"Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021","volume":"23","author":"Banerjee","year":"2022","journal-title":"BMC Nephrol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","article-title":"Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease","volume":"40","author":"Alicic","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B75","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/14656566.2022.2054699","article-title":"Recent advances in the pharmacotherapeutic management of diabetic kidney disease","volume":"23","author":"Block","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2023.104178","article-title":"Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years","volume":"52","author":"Block","year":"2023","journal-title":"Press Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60111821","article-title":"Proteinuria and progression of renal damage: the main pathogenetic mechanisms and pharmacological approach","volume":"60","author":"Longhitano","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.S535437","article-title":"Bosentan Delivery via Nano Metal-Organic Framework nanoMIL-89 Restores Vascular Homeostasis in Pulmonary Arterial Hypertension","volume":"20","author":"Al-Badr","year":"2025","journal-title":"Int J Nanomed"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad266","article-title":"Should we enlarge the indication for kidney biopsy in patients with diabetes? The pro part","volume":"17","author":"Gesualdo","year":"2024","journal-title":"Clin Kidney J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.62347\/qqmx6273","article-title":"The interplay between endothelial cell dysfunction and podocyte injury in diabetic nephropathy: a comprehensive review of current evidence","volume":"17","author":"Guo","year":"2025","journal-title":"Am J Transl Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1631053","article-title":"Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med (Laus)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108357","article-title":"Present and future directions in diabetic kidney disease","volume":"36","author":"Limonte","year":"2022","journal-title":"J Diabetes Complic"},{"key":"B83","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000504623","article-title":"The role of endothelin and endothelin antagonists in chronic kidney disease","volume":"6","author":"Raina","year":"2020","journal-title":"Kidney Dis (Basel)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae072","article-title":"Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease","volume":"17","author":"Ivkovi\u0107","year":"2024","journal-title":"Clin Kidney J"},{"key":"B85","article-title":"Conservative therapy in CKD: new frontiers","volume":"41","author":"Ruotolo","year":"2024","journal-title":"G Ital Nefrol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12882-025-04358-y","article-title":"Association between high-sensitivity C-reactive protein and diabetic nephropathy: a systematic review and meta-analysis","volume":"26","author":"Bassami","year":"2025","journal-title":"BMC Nephrol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2022-0091","article-title":"The seventeenth international conference on endothelin (ET-17)","author":"Gumz","year":"2022","journal-title":"Can J Physiol Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa013","article-title":"Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy","volume":"35","author":"de Zeeuw","year":"2020","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1808445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:27:50Z","timestamp":1778819270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1808445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":88,"alternative-id":["10.3389\/fendo.2026.1808445"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1808445","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1808445"}}